ImageneBio, Inc. (IMA) Income Statement
IMA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIMA revenue and net income
Where IMA's revenue goes
2025Each bar shows an amount and its share of revenue. IMA kept −5,668.6% of revenue as net income.
IMA profit margins
IMA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −77.1% | −62.9% | −38.6% | — |
| Gross profit | −111.8% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IMA quarterly EPS vs estimates
ImageneBio beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.83).
IMA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $800,000 | $3.5M | $9.2M | $15.6M | $31.0M | $9.2M | $13.8M | $990,000 |
| Cost of revenue | $1.0M | $1.5M | $1.0M | $64.3M | $47.1M | $44.8M | $24.9M | $39.0M |
| Gross profit | −$233,000 | $2.0M | $8.1M | −$48.7M | −$16.1M | −$35.7M | −$11.2M | −$38.0M |
| Research & development | $28.5M | $32.1M | $59.7M | $64.3M | $47.1M | $44.8M | $24.9M | $38.6M |
| Sales, general & admin | $20.7M | $8.4M | $24.9M | $22.2M | $18.0M | $8.9M | $7.3M | $2.9M |
| Total operating expenses | $48.2M | $39.0M | $83.6M | $22.2M | $18.0M | $8.9M | $7.3M | $41.5M |
| Operating income | −$48.5M | −$37.0M | −$75.4M | −$70.9M | −$34.1M | −$44.5M | −$18.5M | −$40.9M |
| Interest income | — | $374,000 | $1.2M | — | — | — | — | — |
| Income before taxes | −$45.7M | −$36.6M | −$68.3M | −$68.8M | −$34.1M | −$44.3M | −$16.8M | −$40.9M |
| Income taxes | −$350,000 | $13,000 | −$162,000 | −$2.1M | $307,442 | — | $71,140 | — |
| Net income | −$45.3M | −$36.6M | −$68.2M | −$68.8M | −$34.1M | −$44.3M | −$16.8M | −$40.9M |
| EBITDA | −$44.7M | −$35.0M | −$67.3M | −$68.0M | −$33.6M | −$44.2M | −$18.2M | −$40.4M |
| EPS (diluted) | −$4.39 | −$1.02 | −$1.64 | −$1.91 | −$4.74 | −$0.15 | −$5.63 | — |
| Gross margin | −29.1% | 56.4% | 88.9% | −311.8% | −52.0% | −387.8% | −81.3% | −3,838.0% |
| Operating margin | −6,056.4% | −1,057.1% | −823.3% | −454.0% | −110.2% | −484.2% | −134.5% | −4,130.7% |
| Net margin | −5,668.6% | −1,044.8% | −744.2% | −440.3% | −110.1% | −481.4% | −122.3% | −4,127.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $800,000 | $0 | $3.5M | $0 | $0 | $659,000 | $1.2M |
| Cost of revenue | — | $174,000 | $561,000 | −$3.3M | $45,000 | $3.7M | $4.6M | $6.8M | $400,000 | $9.6M | $305,000 | $242,000 |
| Gross profit | — | −$174,000 | −$561,000 | $4.1M | −$45,000 | $800,000 | −$4.6M | −$6.8M | −$400,000 | −$9.6M | $354,000 | $943,000 |
| Research & development | $6.7M | $6.0M | $5.2M | $15.6M | $4.0M | $4.0M | $4.6M | $6.8M | $9.8M | $9.6M | $14.0M | $1.2M |
| Sales, general & admin | $5.1M | $6.1M | $370,000 | $11.0M | $4.4M | $2.8M | $7.6M | $4.8M | $5.3M | $6.0M | $8.3M | $6.0M |
| Total operating expenses | $11.8M | $11.9M | $7.9M | $26.6M | $8.7M | $6.8M | $7.9M | $5.6M | $15.4M | $8.6M | $22.3M | $20.4M |
| Operating income | −$11.8M | −$12.1M | −$8.5M | −$26.6M | −$8.8M | −$6.0M | −$12.5M | −$12.4M | −$15.8M | −$18.2M | −$21.9M | −$19.5M |
| Interest expense | — | $1.1M | — | $96,000 | — | — | — | — | — | — | $1.3M | — |
| Income before taxes | −$10.2M | −$10.6M | −$7.2M | −$24.9M | −$2.8M | −$6.1M | −$9.1M | −$10.2M | −$13.7M | −$16.1M | −$19.7M | −$17.3M |
| Income taxes | $16,000 | $10,000 | −$276,000 | −$74,000 | $15,000 | $28,000 | $53,000 | $10,000 | $62,000 | $27,000 | −$162,000 | — |
| Net income | −$10.2M | −$10.6M | −$6.9M | −$24.8M | −$2.8M | −$6.1M | −$9.1M | −$10.2M | −$13.7M | −$16.1M | −$19.5M | −$17.3M |
| EBITDA | −$10.0M | −$11.9M | −$6.6M | −$24.4M | −$8.4M | −$5.9M | −$12.1M | −$11.5M | −$15.0M | −$15.4M | −$18.1M | −$17.1M |
| EPS (diluted) | −$0.63 | −$0.95 | −$0.62 | −$2.91 | −$0.69 | −$0.17 | −$0.20 | −$0.21 | −$0.28 | −$0.33 | −$0.41 | −$0.40 |
| Gross margin | — | — | — | — | — | 100.0% | — | −194.8% | — | — | 53.7% | 79.6% |
| Operating margin | — | — | — | — | — | −749.4% | — | −354.5% | — | — | −3,324.4% | −1,645.8% |
| Net margin | — | — | — | — | — | −759.6% | — | −292.4% | — | — | −2,957.4% | −1,463.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IMA's financial statements (latest annual report filed March 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IMA financial results
In fiscal year 2025 (ended December 31, 2025), ImageneBio reported revenue of $0.8 million, down 77.1% from the year before. It had a net loss of $45.3 million, a net profit margin of −5,668.6%. Diluted earnings per share came to −$4.39. Over five years revenue grew at an average rate of −38.6% a year.
See the IMA stock overview for the latest quote and news, or the IMA chart for price history and technical indicators.
IMA income statement FAQ
What is ImageneBio's annual revenue?
ImageneBio reported total revenue of $0.8 million for fiscal year 2025, which ended on December 31, 2025. That was down 77.1% from $3.5 million the previous year.
Is ImageneBio profitable?
No. ImageneBio reported a net loss of $45.3 million in fiscal 2025, a net profit margin of −5,668.6%; its operating margin was −6,056.4%.
What is ImageneBio's gross margin?
ImageneBio's gross margin was −29.1% in fiscal 2025: for every $100 of revenue, ImageneBio kept $-29 after the direct cost of its products and services.
How much does ImageneBio spend on research and development?
ImageneBio spent $28.5 million on research and development in fiscal 2025, 3,565.6% of revenue.
How fast is ImageneBio growing?
Revenue grew −38.6% a year on average over the last five fiscal years, from $9.2 million to $0.8 million.
What are ImageneBio's earnings per share?
ImageneBio earned $-4.39 per diluted share in fiscal 2025, compared with $-1.02 a year earlier.
When will ImageneBio report its next earnings?
ImageneBio is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does ImageneBio's fiscal year end?
ImageneBio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 10, 2026.